Previous close | 1.4000 |
Open | 1.4900 |
Bid | 1.0500 |
Ask | 1.5500 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 1.2500 - 1.6000 |
Contract range | N/A |
Volume | |
Open interest | 2.1k |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.